Moderna (MRNA) excited analysts, though not as much investors, with its announcement this week that it planned to file for approval of its mRNA vaccine designed to protect older adults against respiratory syncytial virus (RSV) after it demonstrated success in a Phase III trial.
After…
Source: www.genengnews.com – Read more
Six million Qantas customers hit in cyber attack – The Australian
Summarize this content to a maximum of 60 words: Six million Qantas customers hit in cyber attack The Australian
